RPG Life SciencesNSE:RPGLIFE +0.92%92 Current Ratio is 3.48 as of Mar. 2026, which is 55% above its 10-year median of 2.25. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 92/100 and a GF Value™ of ₹2,353.32 (Fairly Valued). The stock has 5 warning signs investors should review. Among 997 Drug Manufacturers companies, RPG Life Sciences ranks better than 72.92% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. RPG Life Sciences's current ratio for the quarter that ended in Mar. 2026 was 3.48.
RPG Life Sciences has a current ratio of 3.48. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for RPG Life Sciences's Current Ratio or its related term are showing as below:
NSE:RPGLIFE'
s Current Ratio Range Over the Past 10 Years
Min: 1.18 Med: 2.25 Max: 3.88
Current: 3.48
During the past 13 years, RPG Life Sciences's highest Current Ratio was 3.88. The lowest was 1.18. And the median was 2.25.
NSE:RPGLIFE's Current Ratio is ranked better than 72.92% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:RPGLIFE: 3.48
RPG Life Sciences (NSE:RPGLIFE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
RPG Life Sciences Current Ratio Related Terms
RPG Life Sciences Current Ratio Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RPGLIFE vs ZTS, UTHR: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPG Life Sciences (NSE:RPGLIFE) has a Current Ratio of 3.48 as of Mar. 2026. This is 55% above median its historical median of 2.25. Over the past decade, RPG Life Sciences' Current Ratio has ranged from 1.18 to 3.88. According to the industry distribution chart, RPG Life Sciences ranks #270 out of 997 companies in the Drug Manufacturers industry, placing it in the top 27.1%.
Is RPG Life Sciences' Current Ratio too high?
RPG Life Sciences' current Current Ratio of 3.48 is 55% above median its 10-year median of 2.25. Over the past 10 years, this metric has ranged from a low of 1.18 to a high of 3.88. The Drug Manufacturers industry median Current Ratio is 2.00. RPG Life Sciences' value of 3.48 is 74% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #270 out of 997 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, RPG Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #270 out of 997 companies for Current Ratio. This puts RPG Life Sciences in the upper half of its industry. The industry median Current Ratio is 2.00. RPG Life Sciences' value of 3.48 is 74% above this benchmark. Historically, RPG Life Sciences' own Current Ratio has ranged from 1.18 to 3.88 over the past decade. While the company's 10-year median is 2.25 vs. the industry median of 2.00, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current Current Ratio of 3.48 is 74% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current Current Ratio is 3.48, which is 55% above median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,353.32, compared to a current price of ₹2,415.80 — trading 2.7% above its estimated fair value. The current Current Ratio is 3.48, which is 55% above median its 10-year median of 2.25 and 74% above the Drug Manufacturers industry median of 2.00. RPG Life Sciences' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current Current Ratio is 3.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,415.80 is trading 2.7% above its estimated GF Value™ of ₹2,353.32.
GuruFocus considers RPG Life Sciences to be Fairly Valued.
Key valuation signals for NSE:RPGLIFE:
Current Ratio: 3.48 (55% above median its 10-year median of 2.25)
GF Value™: ₹2,353.32 vs. price of ₹2,415.80 (2.7% above fair value)
Industry Position: 74% above the Drug Manufacturers median (#270 of 997)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
92GF Score
Get the complete analysis for NSE:RPGLIFE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
